Literature DB >> 22228967

An update on chemotherapy of colorectal liver metastases.

Chen-Chen Wang1, Jin Li.   

Abstract

Surgical resection of liver metastases of colorectal cancer greatly improves the clinical outcome of patients with advanced disease. Developments in chemotherapeutic agents and strategies bring hope of a cure to patients with initially unresectable colorectal liver metastases (CLM). Perioperative chemotherapy significantly improves the survival time of patients who receive curative-intent hepatectomy. Even for unresectable CLM, recent studies demonstrated that active preoperative chemotherapy could achieve shrinkage of liver metastasis and thus render some for resection. Furthermore, an increase in tumor resection rate and prolonged survival time among patients with CLM has been observed following the application of monoclonal antibodies in recent years. However, the value of chemotherapy via hepatic arterial infusion is still unclear. More trials should be conducted in patients with CLM in order to improve survival.

Entities:  

Keywords:  Chemotherapy; Colorectal cancer; Liver metastases; Resection rate; Targeted agents

Mesh:

Substances:

Year:  2012        PMID: 22228967      PMCID: PMC3251802          DOI: 10.3748/wjg.v18.i1.25

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  54 in total

1.  Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer.

Authors:  N Kemeny; Y Huang; A M Cohen; W Shi; J A Conti; M F Brennan; J R Bertino; A D Turnbull; D Sullivan; J Stockman; L H Blumgart; Y Fong
Journal:  N Engl J Med       Date:  1999-12-30       Impact factor: 91.245

2.  Evaluation of aggressively treated patients with unresectable multiple liver metastases from colorectal cancer.

Authors:  Nobutomo Miyanari; Takeo Mori; Keiichi Takahashi; Masamichi Yasuno
Journal:  Dis Colon Rectum       Date:  2002-11       Impact factor: 4.585

3.  Prospective randomised trial on adjuvant hepatic-artery infusion chemotherapy after R0 resection of colorectal liver metastases.

Authors:  C Rudroff; A Altendorf-Hoffmann; R Stangl; J Scheele
Journal:  Langenbecks Arch Surg       Date:  1999-06       Impact factor: 3.445

4.  Liver resection for colorectal metastases.

Authors:  Y Fong; A M Cohen; J G Fortner; W E Enker; A D Turnbull; D G Coit; A M Marrero; M Prasad; L H Blumgart; M F Brennan
Journal:  J Clin Oncol       Date:  1997-03       Impact factor: 44.544

5.  Downstaging by regional chemotherapy of non-resectable isolated colorectal liver metastases.

Authors:  K H Link; J Pillasch; A Formentini; E Sunelaitis; G Leder; F Safi; M Kornmann; H G Beger
Journal:  Eur J Surg Oncol       Date:  1999-08       Impact factor: 4.424

Review 6.  Treatment of liver metastases, an update on the possibilities and results.

Authors:  T Ruers; R P Bleichrodt
Journal:  Eur J Cancer       Date:  2002-05       Impact factor: 9.162

Review 7.  Chemotherapy and surgery: new perspectives on the treatment of unresectable liver metastases.

Authors:  R Adam
Journal:  Ann Oncol       Date:  2003       Impact factor: 32.976

8.  Neoadjuvant treatment of unresectable liver disease with irinotecan and 5-fluorouracil plus folinic acid in colorectal cancer patients.

Authors:  C Pozzo; M Basso; A Cassano; M Quirino; G Schinzari; N Trigila; M Vellone; F Giuliante; G Nuzzo; C Barone
Journal:  Ann Oncol       Date:  2004-06       Impact factor: 32.976

9.  Survival and recurrence after neo-adjuvant chemotherapy and liver resection for colorectal metastases: a ten year study.

Authors:  N D Karanjia; J T Lordan; W J Fawcett; N Quiney; T R Worthington
Journal:  Eur J Surg Oncol       Date:  2008-11-17       Impact factor: 4.424

10.  Factors influencing the natural history of colorectal liver metastases.

Authors:  R Stangl; A Altendorf-Hofmann; R M Charnley; J Scheele
Journal:  Lancet       Date:  1994-06-04       Impact factor: 79.321

View more
  27 in total

Review 1.  Treatment Options in Oligometastatic Disease: Stereotactic Body Radiation Therapy - Focus on Colorectal Cancer.

Authors:  Aaron T Wild; Yoshiya Yamada
Journal:  Visc Med       Date:  2017-02-03

2.  Patients with multiple synchronous colonic cancer hepatic metastases benefit from enrolment in a "liver first" approach protocol.

Authors:  Dimitrios Kardassis; Achilleas Ntinas; Dimosthenis Miliaras; Alexandros Kofokotsios; Konstantinos Papazisis; Dionisios Vrochides
Journal:  World J Hepatol       Date:  2014-07-27

Review 3.  Anti-EGFR and anti-VEGF agents: important targeted therapies of colorectal liver metastases.

Authors:  Qing-Yang Feng; Ye Wei; Jing-Wen Chen; Wen-Ju Chang; Le-Chi Ye; De-Xiang Zhu; Jian-Min Xu
Journal:  World J Gastroenterol       Date:  2014-04-21       Impact factor: 5.742

4.  Retrospective analysis of pathological response in colorectal cancer liver metastases following treatment with bevacizumab.

Authors:  R Vera; M Gomez Dorronsoro; S Lopez-Ben; A Viudez; B Queralt; I Hernandez; M R Ortiz-Duran; C Zazpe; J Soriano; I Amat; J Herrera Cabezón; E Diaz; A Codina-Barreras; X Hernandez-Yagüe; A Quera; J Figueras
Journal:  Clin Transl Oncol       Date:  2013-12-12       Impact factor: 3.405

5.  Beyond KRAS: Predictive factors of the efficacy of anti-EGFR monoclonal antibodies in the treatment of metastatic colorectal cancer.

Authors:  Alfonso De Stefano; Chiara Carlomagno
Journal:  World J Gastroenterol       Date:  2014-08-07       Impact factor: 5.742

6.  Stereotactic radiation therapy in oligometastatic colorectal cancer: outcome of 102 patients and 150 lesions.

Authors:  V Dell'Acqua; A Surgo; F Kraja; J Kobiela; Maria Alessia Zerella; P Spychalski; S Gandini; C M Francia; D Ciardo; C Fodor; A M Ferrari; G Piperno; F Cattani; S Vigorito; F Pansini; W Petz; R Orecchia; M C Leonardi; B A Jereczek-Fossa
Journal:  Clin Exp Metastasis       Date:  2019-06-04       Impact factor: 5.150

Review 7.  Cytoreductive surgery and intraperitoneal chemotherapy for colorectal peritoneal metastases.

Authors:  Reza Mirnezami; Brendan J Moran; Kate Harvey; Tom Cecil; Kandiah Chandrakumaran; Norman Carr; Faheez Mohamed; Alexander H Mirnezami
Journal:  World J Gastroenterol       Date:  2014-10-14       Impact factor: 5.742

Review 8.  Liver metastatic disease: new concepts and biomarker panels to improve individual outcomes.

Authors:  Olga Golubnitschaja; Krishna Chander Sridhar
Journal:  Clin Exp Metastasis       Date:  2016-08-19       Impact factor: 5.150

9.  A phase I trial of isolated hepatic perfusion (IHP) using 5-FU and oxaliplatin in patients with unresectable isolated liver metastases from colorectal cancer.

Authors:  D Magge; A H Zureikat; D L Bartlett; M P Holtzman; H A Choudry; J H Beumer; J F Pingpank; J L Holleran; S Strychor; D E Cunningham; H L Jones; H J Zeh
Journal:  Ann Surg Oncol       Date:  2013-04-11       Impact factor: 5.344

10.  TAGLN suppresses proliferation and invasion, and induces apoptosis of colorectal carcinoma cells.

Authors:  Qinmin Li; Ruihua Shi; Yundong Wang; Xiaoping Niu
Journal:  Tumour Biol       Date:  2012-11-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.